Raxatrigine

From Wikipedia, the free encyclopedia
  (Redirected from CNV1014802)
Jump to: navigation, search
Raxatrigine
Raxatrigine.svg
Systematic (IUPAC) name
(2S,5R)-5-[4-[(2-fluorophenyl)methoxy]phenyl]pyrrolidine-2-carboxamide
Clinical data
Routes of
administration
Oral
Identifiers
CAS Number 934240-30-9
934240-35-4 (mesylate)
ATC code None
PubChem CID 16046068
ChemSpider 13174481
Chemical data
Formula C18H19FN2O2
Molar mass 314.354063 g/mol

Raxatrigine (INN, USAN) (formerly CNV1014802, GSK-1014802) is a novel analgesic under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).[1][2][3] It acts as a selective, small-molecule, state-dependent Nav1.7 voltage-gated sodium channel blocker.[1][2] In June 2014, Convergence presented positive results for a phase II clinical study of raxatrigine in the treatment of TGN, including findings that the drug had an excellent efficacy and safety profile and was well-tolerated.[4][non-primary source needed]

See also[edit]

References[edit]

  1. ^ a b Convergence Pharmaceuticals. "CNV1014802 - Convergence Pharmaceuticals". 
  2. ^ a b Stephen McMahon; Martin Koltzenburg; Irene Tracey; Dennis C. Turk (1 March 2013). Wall & Melzack's Textbook of Pain: Expert Consult - Online. Elsevier Health Sciences. p. 508. ISBN 0-7020-5374-0. 
  3. ^ Bagal, Sharan K.; Chapman, Mark L.; Marron, Brian E.; Prime, Rebecca; Ian Storer, R.; Swain, Nigel A. (2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters 24 (16): 3690–9. doi:10.1016/j.bmcl.2014.06.038. ISSN 0960-894X. PMID 25060923. 
  4. ^ MarketWatch (2014). "Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study".